Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
暂无分享,去创建一个
[1] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[2] T. Baillie,et al. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. , 2006, Chemical research in toxicology.
[3] Jing Lin,et al. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. , 2003, Current topics in medicinal chemistry.
[4] B. Corrigan,et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[5] T. Baillie,et al. Organic Chemistry in Drug Discovery , 2004, Science.
[6] Thomayant Prueksaritanont,et al. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. , 2006, Toxicology and applied pharmacology.
[7] Dominic P. Williams,et al. Toxicophores: investigations in drug safety. , 2006, Toxicology.
[8] Desmond O'Connor,et al. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. , 2005, Rapid communications in mass spectrometry : RCM.
[9] Dominic P. Williams,et al. Selection of new chemical entities with decreased potential for adverse drug reactions. , 2006, European journal of pharmacology.
[10] A. Seeringer,et al. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.
[11] R Scott Obach,et al. Metabolites and safety: What are the concerns, and how should we address them? , 2006, Chemical research in toxicology.
[12] Dominic P. Williams,et al. Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.
[13] J. Uetrecht,et al. Idiosyncratic drug reactions: current understanding. , 2007, Annual review of pharmacology and toxicology.
[14] T. Baillie,et al. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. , 2004, Analytical chemistry.
[15] F. Guengerich,et al. Untargeted analysis of mass spectrometry data for elucidation of metabolites and function of enzymes. , 2007, Analytical chemistry.
[16] L. Benet,et al. IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY , 2006, Drug Metabolism and Disposition.
[17] M. Huang,et al. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.
[18] Albert P. Li,et al. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. , 2002, Chemico-biological interactions.
[19] Jiunn H Lin,et al. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. , 2007, Current drug metabolism.
[20] L. Chinn,et al. ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.
[21] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[22] Bradley L Urquhart,et al. Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.
[23] M. Fromm,et al. Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.
[24] T. Yokoi,et al. Application of Chimeric Mice with Humanized Liver for Predictive ADME , 2007, Drug metabolism reviews.
[25] B. Warrack,et al. Utility of the hybrid LTQ-FTMS for drug metabolism applications. , 2006, Current drug metabolism.
[26] Lippincott-Schwartz,et al. Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .
[27] M. Hutzler,et al. Predicting drug-drug interactions in drug discovery: where are we now and where are we going? , 2005, Current opinion in drug discovery & development.
[28] Michael McMillian,et al. Application of genomics in preclinical drug safety evaluation. , 2006, Basic & clinical pharmacology & toxicology.
[29] M. Beconi,et al. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. , 2005, Journal of pharmacological and toxicological methods.
[30] A. Y. Lu,et al. Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective. , 2005, Current drug metabolism.
[31] D. Liebler,et al. Protein targets of reactive electrophiles in human liver microsomes. , 2007, Chemical research in toxicology.
[32] Ulf Norinder,et al. Prediction of ADMET Properties , 2006, ChemMedChem.
[33] J. Brockmöller,et al. Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs , 2005, Clinical pharmacokinetics.
[34] R. Snyder,et al. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. , 2006, Pharmacogenomics.
[35] James L Stevens,et al. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here? , 2006, Chemical research in toxicology.
[36] W. Evans. Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy , 2004, Therapeutic drug monitoring.
[37] R. Weinshilboum,et al. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.
[38] Michelle L. Reyzer,et al. MALDI-MS-based imaging of small molecules and proteins in tissues. , 2007, Current Opinion in Chemical Biology.
[39] Ernesto Callegari,et al. A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.
[40] J. Woodcock,et al. The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.
[41] Leslie Z Benet,et al. Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems , 2006, Journal of Pharmacology and Experimental Therapeutics.
[42] Karen L Davis-Bruno,et al. A regulatory perspective on issues and approaches in characterizing human metabolites. , 2006, Chemical research in toxicology.
[43] S. Walker,et al. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.
[44] W Griffith Humphreys,et al. Safety assessment of drug metabolites: Characterization of chemically stable metabolites. , 2006, Chemical research in toxicology.
[45] M. Fielden,et al. The state-of-the-art in predictive toxicogenomics. , 2006, Current opinion in drug discovery & development.
[46] R. Aebersold,et al. Mass Spectrometry and Protein Analysis , 2006, Science.
[47] A. D. Rodrigues,et al. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. , 2002, Current drug metabolism.
[48] T. Baillie,et al. Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.
[49] A. Nassar,et al. Strategies for dealing with reactive intermediates in drug discovery and development. , 2004, Current opinion in drug discovery & development.
[50] J. Bolton,et al. Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study. , 2005, Chemical research in toxicology.
[51] F. Guengerich,et al. Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.
[52] J. Waring,et al. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. , 2005, Current opinion in drug discovery & development.
[53] N. Risch,et al. Functional genomics of membrane transporters in human populations. , 2005, Genome research.
[54] R. Cooks,et al. Ambient Mass Spectrometry , 2006, Science.
[55] F Peter Guengerich,et al. Applying mechanisms of chemical toxicity to predict drug safety. , 2007, Chemical research in toxicology.
[56] Judy Lieberman,et al. Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.
[57] Karen Brown,et al. Applications of accelerator mass spectrometry for pharmacological and toxicological research. , 2006, Mass spectrometry reviews.
[58] H. Greenberg,et al. American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process , 2007, Journal of clinical pharmacology.